SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity.
Screening of cDNA expression libraries derived from human tumors with autologous sera (SEREX) permits the definition of immunogenic antigens in individual cancer patients. However, only a minority of SEREX-derived cDNA clones show a clear cancer-relatedness in the sense that circulating autoantibodies to them occur exclusively in the sera of tumor patients but not in healthy individuals. Evaluation of multiple SEREX-defined clones in serological assays using panels of allogeneic sera from cancer patients as well as appropriate control groups is an important step towards focussing on the relevant antigens. This in turn is the basis for defining disease parameters of diagnostic and prognostic significance.Here, we show that seroreactivity of multiple SEREX-derived antigens can be simultaneously evaluated using a rapid and versatile high throughput procedure, which we call SeroGRID.
Krause
Patricia
P
III. Department of Internal Medicine, Johannes Gutenberg University Mainz, Obere Zahlbacherstr. 63, D-55131 Mainz, Germany.
Türeci
Ozlem
O
Micke
Patrick
P
Buhl
Roland
R
Huber
Christoph
C
Sahin
Ugur
U
D000951:Antigens, Neoplasm / Q000097:blood / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D010582:Bacteriophage lambda / Q000276:immunology; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D015723:Gene Library; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology
D000951:Antigens, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D011994:Recombinant Proteins